Kyverna Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $483.9M
- Price
- $7.91
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.68%
- Volume
- 431.8K
About
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Quick stats
Shares outstanding60.8M
Computed float36.8M
Float / shares60.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001994702
Websitehttps://kyvernatx.com
AI Summary
AI-generated1/13
standardbullishpartnership
Kyverna Therapeutics and ElevateBio Enter into Commercial Manufacturing and Supply Agreement for Miv-cel
Kyverna Therapeutics entered a commercial manufacturing and supply agreement with ElevateBio for miv-cel, its autologous CD19-directed CAR T-cell therapy candidate.
The deal ensures scalable supply for potential launches in stiff person syndrome and generalized myasthenia gravis, supported by ElevateBio’s demonstrated clinical manufacturing success rate of over 98%.
Kyverna remains on track to complete its rolling BLA submission for miv-cel in SPS in the fourth quarter of 2026.